Matrix metalloproteinases (MMPs) contribute to the joint damage in rheumatoid arthritis (RA). Less is known of the involvement of MMPs at extra-articular sites of rheumatoid inflammation. We assessed the relative contribution from MMP-1, MMP-3, MMP-7 and MMP-12 to joint and extra-articular tissue destruction and inflammation by comparing gene expression in joint synovia and subcutaneous rheumatoid nodules from RA patients. Expression of MMP-1 and MMP-3 predominated in synovia, whereas MMP-12 expression was significantly higher in rheumatoid nodules. Markedly higher MMP-7 expression distinguished a subgroup of nodules that featured infiltrating monocyte/macrophage-producing MMP-7 protein. The high MMP-7 expression in nodules was associated with the single-nucleotide polymorphism (SNP) rs11568818 ( À 181A4G, MMP-7 promoter) and more active inflammation within the nodule lesions. Patients with such nodules had significantly earlier age of RA onset. Our findings indicate that the expression of MMP-1 and MMP-3 occurs relatively independent of the tissue microenvironment with substantial expression also at extra-articular sites. MMP-12 expression reflects the involvement of monocyte/macrophages in rheumatoid inflammation. Evidence for the association between the rs11568818 SNP and increased MMP-7 expression is restricted to nodules, which indicates that consequences of the MMP-7 polymorphism are likely to manifest within aspects of immune/inflammatory activity that are monocyte/macrophage-mediated.
INTRODUCTION
Rheumatoid arthritis (RA) is a prototypic chronic, inflammatory disease. The principal clinical feature is progressive destruction of joint tissue components, loss of function and disability. 1 Destruction of extra-articular tissues may also be observed, such as the development of subcutaneous rheumatoid nodules. Nodules occur in 25-30% of cases and are generally associated with more severe disease. 2 The subcutaneous rheumatoid nodule is a necrotising granuloma that has a highly organised and uniform structure. 3 The centre of the nodule comprises necrotic tissue that includes deposits of necrotic collagen and reticulin fibres admixed with fibrinoid material, cellular debris and substantial amounts of S100 proteins. 2, 4 This necrotic centre is surrounded by a 'palisade' of monocyte/macrophages infiltrating from the vascular periphery. 3 T cells and putative dendritic cells colocalise immediately outside the 'palisade' layer and in the perivascular area. [5] [6] [7] While plasma cells may be present, there is no significant B-lymphocyte component to the inflammatory infiltrate in subcutaneous nodules. 8 Tissue destruction is a feature of both the rheumatoid nodule and joint synovial lesions in RA. 8 The irreversible destruction of cartilage, tendon and bone that comprise the synovial joints is well documented. Inflammatory cytokines, including tumour necrosis factor (TNF)-a and interleukin (IL)-1b, 9 ,10 stimulate the production of matrix metalloproteinases (MMPs), including MMP-1 and MMP-3 that, respectively, target collagenous and noncollagen components of the extracellular matrix. [11] [12] [13] Much less is known of the tissue-destructive process in rheumatoid nodules or the contribution MMPs make towards inflammation in this extra-articular lesion. The expression of MMP-2, MMP-3 and MMP-9 proteins has been noted previously in rheumatoid nodules, as part of an active granulomatous inflammation. 14 In other granulomas, MMP-9 and MMP-12 emerge as mediators of the extensive connective tissue destruction and/or tissue remodelling. [15] [16] [17] In a comparison of gene expression between inflamed RA synovium and subcutaneous nodules, our preliminary data highlighted two further members of the MMP enzyme family, MMP-7 (matrilysin-1; PUMP-1) and MMP-12 (macrophage elastase), both with functions that may contribute to the granulomatous inflammation and tissue destruction seen in rheumatoid nodules.
MMP-7 is distinct among the MMP family as it lacks the carboxyl-terminal haemopexin-like domain common to all other members that would normally function to restrict substrate specificity. 18 Consequently, MMP-7 possesses potent and broad proteolytic activity. MMP-7 is produced by a variety of normal cells, including glandular and mucosal epithelial cells, keratinocytes, fibroblasts 18 and also by monocyte/macrophages at various stages of their differentiation.
inflammation, through its effect upon several matrix components, including elastin and basement membrane proteins. 23 Owing to the functional redundancy among MMP family members, the biological relevance of an individual MMP is primarily determined by its particular pattern of expression. 24 In tissues affected by inflammation, multiple signalling pathways that involve glucocorticoids, transforming growth factor-b, TNF-a, IL-1b, IL-6 or interferon (IFN)-g have been shown to regulate MMP gene expression. 25 Sequence variations within gene promoter regions are also associated with altered MMP gene expression. [26] [27] [28] For the MMP-7 promoter, both an A to G transition at the À 181-bp position ( À 181A4G; rs11568818), and a C to T substitution at position À 153 ( À 153C4T; rs11568819) have been shown to increase MMP-7 gene expression in vitro. 26 Consequently, the activity of the À 181G allele promoter region is about two-to threefold higher with an associated increase in protein expression. 26 In genetic association studies, the MMP-7 À 181A4G polymorphism has been associated with increased risk of several cancers, [29] [30] [31] coronary artery disease 26 and, recently, with the degree of disability in RA. 32 This study compared expression of the MMP-1, MMP-3, MMP-7 and MMP-12 genes in RA synovial tissue with that in extraarticular nodule lesions. Increased MMP-7 gene expression was found in a subgroup of rheumatoid nodules that was associated with the À 181A4G polymorphism in the MMP-7 promoter region and manifest solely in nodules. This is first genotype-phenotype study, which links the À 181A4G polymorphism and increased MMP-7 expression in the tissue-destructive inflammatory lesions of RA.
RESULTS
MMP expression in rheumatoid synovial and nodule tissues Expression levels of the genes MMP-1, MMP-3, MMP-7 and MMP-12 were compared in rheumatoid synovial and nodule tissues (Table 1) using real-time polymerase chain reaction (RT-PCR) analysis. Both MMP-1 and MMP-3 expressions were significantly higher in synovia compared with nodule tissues (Po0.0001; Figure 1a ). In contrast, MMP-12 expression was significantly higher in nodule tissues when compared with the synovial tissue (Po0.001; Figure 1a ). Although the analysis showed no difference overall in MMP-7 gene expression between synovial and nodule tissues (P40.05; Figure 1a ), we did observe noticeably higher MMP-7 expression in a subgroup of individual nodule tissues. To facilitate further study, we distinguished high or low MMP-7 expression as levels of gene expression above a nominal threshold (1.20 ng of gene-specific RNA), defined by the nodule group mean ± 1 s.e. By this criterion, 7 of 24 nodules (29%) showed significantly higher MMP-7 expression (2.73±1.73 ng RNA; mean±s.d.) when compared with remaining nodules with low MMP-7 expression (0.14 ± 0.19 ng RNA; Po0.001) or to levels of MMP-7 expression in all synovial tissues (0.11 ± 0.08; Po0.01; Figure 1b ).
MMP-7 ( À 181A4G) promoter polymorphism is associated with increased MMP-7 expression in rheumatoid nodules
We further investigated whether a genetic predisposition underlies the increased MMP-7 expression observed in a subgroup of rheumatoid nodule tissues. Two functional single-nucleotide polymorphisms (SNPs), À 181A4G and À 153C4T, that occur in the promoter region of the MMP-7 gene were considered. Among the RA patient cohort studied, the À 153TT genotype was not detected, regardless of MMP-7 expression levels. Overall, the analysis showed a different frequency of distribution for the MMP-7 À 181AG and À 181GG genotypes, with the latter significantly more frequent among RA patients with high MMP-7 expression in nodule tissue (P ¼ 0.015; Table 2 ). In contrast, there was no difference in the frequency of distribution for the MMP-7 À 153CT genotype (P40.05; Table 2 ). Figure 2a) . A low prevalence of the À 153C4T SNPs precluded the analysis of MMP-7 expression in relation to haplotypes.
The availability of paired synovial and nodule tissue samples allowed for further examination of any genotype-phenotype association. Analysis of paired synovial and nodule samples from three separate patients showed that increased MMP-7 expression is restricted to nodule tissue in those patients with a À 181GG genotype. These data suggest that the increased MMP-7 expression is dictated by a combination of the nodule tissue microenvironment and MMP-7 ( À 181GG) promoter polymorphism ( Figure 2b ).
Inflammation features associated with MMP-7 expression
The proinflammatory cytokines, TNF-a and IFN-g, make important contributions to the inflammatory environment within the rheumatoid nodule. 8 However, we found no significant association between the expression of either the MMP-7 or MMP-12 genes and the TNF or IFNG gene expression within rheumatoid nodules (data not shown). This was the case for nodules regardless of high or low MMP-7 expression.
To gain further insight into differences between nodules with high or low MMP-7 expression, nodule sections were assessed for collagen content, neutrophil influx and the presence of granuloma. Representative histology and the associated histological scores are shown in Figure 3 (see also Supplementary Figures 1  and 2 ). The collagen in nodules with high MMP-7 expression was more fibrinoid and 'altered' in appearance (Figure 3a and b) when compared with the collagen in nodules with low MMP-7 expression (Figure 3c and d). The latter had prominent areas of intact and dense collagen fibres typical of mature collagen. Corresponding histological scores reflect this appearance showing significantly less amounts of intact and mature collagen in nodule tissues with high MMP-7 expression (arbitrary score 1.7 ± 0.57 vs 2.5 ± 0.55; mean ± s.d.; P ¼ 0.04; Figure 3e ). Nodules with high MMP-7 expression also showed a prominent neutrophil influx (Figure 3b ), observed throughout the tissue including perivascular and necrotic areas. Histological scores for neutrophil influx were significantly higher in nodules with high MMP-7 expression (arbitrary score 1.7±0.91 vs 0.58±0.58; P ¼ 0.05; Figure 3e ). As expected, the degree of granuloma development and associated necrosis was similar in most tissues and appeared unaffected by the levels of MMP-7 expression. Accordingly, there was no significant difference in histological scores for granuloma formation (P ¼ 0.2; Figure 3e ).
With indications of more active inflammation within nodules with high MMP-7 expression, we considered additional demographics for the patients subgrouped by nodule MMP-7 expression (Table 3 ). Age at 'biopsy' between patients contributing nodules with high or low MMP-7 expression was the same. However, patients contributing nodules with high MMP-7 expression were significantly younger when diagnosed with RA and consequently had significantly longer disease duration at the time of 'biopsy', indicating an earlier onset of RA. Measures of serum C-reactive protein and erythrocyte sedimentation rates were similar between the two groups. There was no effect of current or former smoking on MMP-7 expression nor any association with methotrexate therapy (Table 3) .
Different patterns of MMP-12 and MMP-7 protein expression in nodule tissue. Monocyte/macrophages are the principal inflammatory cells infiltrating the nodule. 6, 33 In nodules with high MMP-7 expression, increased neutrophils mean a more varied myeloid cell infiltration. These myeloid cells produce the S100A8 and S100A9 proteins, 4, 34 a characteristic that was used to establish any links between 
Abbreviations: H, high; L, low; MMP, matrix metalloproteinase; RA, rheumatoid arthritis; SNP, single-nucleotide polymorphism; UD, undetermined. MMP-7 or MMP-12 expression and the myeloid cell infiltration. Comparisons of gene expression in rheumatoid nodules found no association between MMP-7 and either CAGA (encoding S100A8) or CAGB (S100A9) expression (data not shown). However, MMP-12 expression was positively and significantly associated with S100A8 gene expression (Spearman's correlation, r ¼ 0.49; P ¼ 0.015; Supplementary Figure 3 ).
Inflammatory cells producing MMP-7 or MMP-12 protein were identified using double immunofluorescence with a combination of antibodies that specifically identified each MMP while distinguishing CD14 þ monocyte/macrophages. Distinctly different patterns of MMP-7 and MMP-12 protein expression were evident in nodules. MMP-7 was produced by a subset of CD14 þ monocyte/macrophages infiltrating the nodule (Figure 4 ). These 
CD14
þ /MMP-7 þ monocyte/macrophages were located in the innermost regions of the palisade layer (Figure 4) .
We also considered whether other inflammatory cells in the nodule are responsible for MMP-7 production. CD3 þ T cells were generally restricted to the perivascular regions in the outer vascular zone of the nodule and did not produce MMP-7 protein. Similarly, CD20
þ B cells were rare in the nodule tissue, but when identified, these isolated individual cells did not produce MMP-7. MMP-12 protein was restricted to CD14 þ monocyte/macrophages in perivascular regions. MMP-12 was neither detected in CD14 þ cells that had infiltrated the tissue beyond the perivascular regions nor in any cells that lacked CD14 expression (Supplementary Figure 3 ).
DISCUSSION
The proteolytic activities of MMPs regulate tissue remodelling (that is, repair and destruction) and influence the pro-and antiinflammatory signals generated during inflammation. In RA, synovial tissue destruction is a well-documented consequence of MMP action and there is increasing recognition of roles for these proteases in mediating the actions of various chemokines and cytokines. 35, 36 Much less is known of the contribution of MMPs to the inflammation and tissue necrosis that is a feature of the rheumatoid nodule. The aim of this study was to identify any differences in the inflammatory environment between joint and extra-articular nodule inflammation in RA, concentrating particularly on the expression of the MMP-1, MMP-3, MMP-7 and MMP-12 genes. The results revealed a differential contribution from MMPs towards joint and extra-articular inflammation in RA. In particular, a pattern of high MMP-7 gene expression was identified, which was restricted to nodule tissue and associated with the À 181 A4G polymorphism (rs11568818).
Our data show substantial expression of both MMP-1 and MMP-3 in synovial and nodule tissues. Several closely linked polymorphisms across the MMP-1 and MMP-3 genetic loci are known to influence the expression of these two MMPs. 28 Ultimately, the circulating levels of these enzymes in RA 28 and, for MMP-3, the level of disease activity in RA are affected. 37 These associations are thought to reflect the local expression and activity of the MMPs within the joint, dictated by a tissue-specific environment, including inflammation. Although we did not assess MMP-1 or MMP-3 polymorphisms, our expression data are consistent with inflamed synovium as a site of significant MMP-1 and MMP-3 gene expression in RA. Moreover, despite less expression in nodules, the actual amount of MMP-1 and MMP-3 transcript is substantial, indicating that extra-articular sites of inflammation are a further source of these two MMPs. It is also worth noting that we found a positive and significant association between MMP-1 and MMP-3 gene expression within both synovial and nodule tissues. Functioning MMP-3 activates a number of other pro-MMPs, and is critical for the processing of pro-MMP-1 to a fully active enzyme. 38, 39 Although the function was not addressed, the association between MMP-1 and MMP-3 gene expression was consistent with the concurrent activation of these enzymes required for function.
In contrast to MMP-1 and MMP-3 expression, we showed significantly increased MMP-12 expression in nodules compared with RA synovial tissues, and overall that MMP-7 gene expression was no different between the synovial and nodule groups. However, a critical observation was that a subgroup of nodules expressed high levels of MMP-7 transcript, suggesting a role for both MMP-7 and MMP-12 in nodule inflammation and tissue remodelling. Interestingly, we found no association between MMP-7 and MMP-12 gene expression in nodule tissue, suggesting that these enzymes are induced independently and have separate roles. Macrophages are an important source of MMP-12 23 and we found that MMP-12 expression in nodules was associated with the expression of S100A8, suggesting that MMP-12 is derived from newly infiltrating monocyte/macrophages. 40 Consistent with this association, MMP-12 protein was restricted to CD14 þ monocyte/ macrophages in perivascular areas of the nodule tissue. This may underlie a direct role for MMP-12 in mediating macrophage trafficking into nodules similar to that shown for macrophage infiltration of synovial tissue and the consequent development of joint inflammatory disease. 41 An additional role for MMP-12 in nodule inflammation that involves chemokine cleavage cannot be discounted. 42 We sought evidence for why high MMP-7 gene expression was restricted to a subgroup of nodules and considered the importance of an underlying genetic component. Two functional polymorphisms, À 181A4G and À 153C4T, in the promoter region of the MMP-7 gene have been shown to increase MMP-7 expression in vitro. 26 Consistent with this, we found that the frequency of the G allele at position À 181 was significantly higher in patients with high MMP-7 expression in nodules, and correspondingly that patients with the variant À 181GG genotype show significantly higher MMP-7 expression in nodules than those with the wild-type AA genotype. This information identifies the presence of the À 181A4G polymorphism as a critical factor that underlies elevated MMP-7 gene expression in rheumatoid nodules. No such association was found with variation in genotype determined by the À 153C4T polymorphism. However, conclusive evidence for any effect of the variant À 153TT genotype awaits further investigation as our patient cohort did not contain any individual with this genotype. This is consistent with the low incidence of this genotype in the general population. 26 Consequently, we were also unable to determine any combined contribution of the À 181A4G and À 153C4T polymorphisms to haplotype that might influence levels of MMP-7 gene expression. Despite the statistical significance of these genetic data, the small sample size within genotype groups requires that any conclusions are moderated. Clearly, a larger sample is needed to gain more confidence in the association between the MMP-7 À 181A4G polymorphism and high MMP-7 expression in nodules.
We identified that a subset of CD14 þ monocytes/macrophages infiltrating the nodules produce MMP-7 protein. The location of these CD14
þ /MMP-7 þ monocyte/macrophages in the innermost regions of the palisade layer, where they are expected to be more mature, 33 but not in the vascular region of nodules, indicates that these are not newly arrived cells. Consistent with this, we found no association between MMP-7 and S100A8 or S100A9 gene expression that would be expected from newly arrived monocytes. 40 Selective expression of MMP-7 in certain monocyte/macrophage subsets has been described previously, related to the site of inflammation and also to the degree of associated inflammatory activity. [19] [20] [21] In an analogous manner, it appears that rheumatoid nodules may also represent a unique site of inflammation. Such a conclusion is reinforced by observations that MMP-7 expression within synovial tissues was consistently low, including in synovia where paired nodules with high MMP-7 expression were available from the same patient.
To assess the inflammatory activity within nodules, we compared the expression of the genes encoding the proinflammatory cytokines, TNF-a and IFN-g. These two cytokines are not expected to influence MMP-7 expression, 19 but they are both established as important mediators of the inflammatory environment within nodules and synovia. 9, 43 However, there was no difference in the expression of these genes between nodules with high MMP-7 expression and those nodules or synovium where MMP-7 expression was lower. Differences in other inflammatory indices, including a greater influx of neutrophils and change in collagen appearance, suggest that there is heightened inflammatory activity in nodules with high MMP-7 expression. All nodules included in this study were long-standing lesions, removed for clinical reasons. Thus, it is more likely that the differences in the inflammation between nodules with high or low MMP-7 expression reflect dynamic changes associated with ongoing or renewed inflammatory activity. Our results indicate that within the context of chronic nodule inflammation, those nodules with high MMP-7 expression are more 'active'. MMP-7 is known to promote neutrophil transmigration and has been proposed to modulate fibrosis signalling in other inflammatory settings. 44, 45 However, heightened inflammatory activity per se was not directly associated with the MMP-7 À 181A4G polymorphism, suggesting that high MMP-7 expression is a consequence rather than a cause of increased inflammation. Similarly, the infiltration of monocyte/macrophages producing MMP-7 protein is also a likely consequence of heightened inflammatory activity. Because MMP-7 displays strong proteolytic activity against a wide variety of extracellular matrix components and also nonextracellular matrix bioactive molecules, like pro-TNF-a, some effect of MMP-7 on nodule pathology is likely. We found that the more 'active' inflammation in nodules is independent of systemic measures of disease activity. Furthermore, there is no evidence that smoking, which worsens established disease or that methotrexate therapy, which can predispose to nodule development, has any influence on MMP-7 expression in nodules. Rather, the onset of RA occurred much earlier in patients with high MMP-7 expression in nodules. Thus, our data suggest a possible association between the presence of the rs11568818 SNP and earlier onset of RA. This possibility also requires confirmation in a larger patient cohort.
In summary, gene expression data suggest more prominent roles for MMP-12 and MMP-7 in the pathogenesis of rheumatoid nodules than in the joint synovium. MMP-7 and MMP-12 expression reflects that monocyte/macrophages are the primary cellular component of nodule inflammation. We further show that high and low MMP-7 gene expression provides a rare basis for subdivision of the extra-articular nodule lesions in rheumatoid inflammation. High MMP-7 gene expression in nodules is predisposed by the À 181A4G polymorphism and associated with heightened inflammatory activity in the lesion. Our data indicate that consequences of the MMP-7 polymorphism are likely to manifest within aspects of immune/inflammatory activity that are monocyte/macrophage-mediated.
PATIENTS AND METHODS

Patients and tissue samples
In all, 11 synovial membrane samples and 24 rheumatoid nodules were obtained from 31 patients, all fulfilling the ACR revised criteria for RA. 46 Patient demographics are summarised in Table 1 . Additional demographics are presented in Table 3 for those patients contributing nodules with high or low MMP-7 expression. Synovial tissue was obtained during joint replacement surgery and nodule tissue following elective surgical removal. Paired synovial and nodule samples were obtained at the same time from three separate patients and two synovial samples were obtained from one other patient, approximately 5 months apart. Human tonsil RNA was used as reference. Ethics approval was obtained from the NZ MultiRegion Ethics Committee.
Quantitation of gene expression by real-time PCR
Total RNA was purified from RA synovial and nodule tissues using an RNeasy mini kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Total RNA (1 mg) was reverse transcribed into complementary DNA using Superscript III (Invitrogen, Carlsbad, CA, USA) primed with oligo(dT) 20 .
Expression of MMP-7, MMP-12, S100A8 and S100A9 genes was assessed by real-time PCR using SYBR GreenER gene expression assays (Invitrogen) on an Applied Biosystems ABI 7300 Sequence Detecting System (Applied Biosystems, Foster City, CA, USA). The SYBR GreenER assay primers were-MMP-7 (sense): 0 , Commercially available TaqMan assays were also used to measure TNF (Hs00174128_m1) and IFN-g (Hs00174143_m1) expression. Test sample threshold cycle (C t ) values were extrapolated to standard curves obtained from human tonsil RNA, to calculate the mean amount of gene-specific RNA in each sample. Using the appropriate assay, results for individual genes were normalised to expression levels of the constitutively expressed gene, glyceraldehede-3-phosphate dehydrogenase (GAPDH), for individual samples.
Genotyping
Genomic DNA was isolated either from 100 mm cryosections of subcutaneous nodules tissue using a ChargeSwitch genomic DNA MicroTissue Kit (Invitrogen) or from peripheral blood using a QIAamp DNA blood mini kit (Qiagen). Both methods followed the manufacturer's instructions.
Genotyping for the MMP-7 À 181A4G and À 153C4T SNPs was performed using PCR-based restriction fragment length polymorphism analysis as described previously. 26 Briefly, the MMP-7 promoter region, from -300 to -22 bp, containing potential MMP-7 -181A4G and/or -153C4T polymorphisms was amplified from genomic DNA and the PCR products were digested with restriction enzymes EcoRI and NlaIII, respectively. For this analysis, the MMP-7 -181A4G primer sets were as follows-MMP-7 -181 A4G (sense): 5 0 -TGGTACCATAATGTCCTGAATG-3 0 , MMP-7 -181 A4G (antisense, mismatch primer): 5 0 -TCGTTATTGGCAGG AAGCACACAATGAATT-3 0 . This antisense primer was mutated from T to A at the equivalent of position -177 bp (underlined) to create an EcoRI recognition site when the -181G allele exists. For analysis of the -153C4T polymorphism, the sense mismatch primer was: 5 0 -ACGAATACA TTGTGTGCTTCCTGCCAATCA-3 0 . This sense primer was mutated from A to C at the equivalent of -155 bp (underlined) to create an NlaIII recognition site when the -153T allele exists. This was paired with the antisense primer: 5 0 -TTTATATAGCTTCTCAGCCTCG-3 0 . A 16 ml aliquot of PCR reaction was subjected to digestion at 37 1C for 3 h in a 20 ml reaction containing 10 U of EcoRI (Roche Applied Science, Mannheim, Germany) or NlaIII (New England Biolabs, Ipswich, MA, USA) as appropriate. Digestion products were separated on a 3% agarose gel and stained with Gel Red (Biotium, Hayward, CA, USA).
In interpreting the PCR-restriction fragment length polymorphism analysis, the -181A and -153C homozygous wild-type alleles are represented as DNA bands of 150 and 160 bp, respectively; the -181G and -153T polymorphic alleles are represented by DNA bands of 120 and 130 bp, respectively. Correspondingly, heterozygous individuals display combinations of 150 and 120 bp for the -181 A4G polymorphism, and 160 and 130 bp for the -153C4T polymorphism. The results of PCR-restriction fragment length polymorphism analysis were confirmed by DNA sequencing of PCR products (Allan Wilson Centre, Massey University, Palmerston North, New Zealand; data not shown).
Double immunofluorescence labelling
Sections (7 mm) of frozen nodule tissues were cut and fixed in acetone for 10 min at 4 1C. After blocking with 5% normal donkey serum (Sigma, Castle Hill, NSW, Australia) for 30 min at room temperature, the sections were incubated overnight at 4 1C with a goat polyclonal antibody against pro-and active MMP-7 (diluted 1:50; R&D Systems, Minneapolis, MN, USA), followed by a 1.5 h incubation with AlexaFluor488-conjugated donkey anti-goat antibody (diluted 1:1500; Invitrogen) at 41 C. The sections were then blocked with normal sheep serum (Sigma) for 30 min at room temperature, and incubated separately with cell-specific mouse monoclonal anti-CD3 (1:100; Dako, Carpenteria, CA, USA), anti-CD20 (1:100; Dako) or anti-CD14 (clone FMC-17; undiluted culture supernatant) for 1 h at room temperature, followed by incubation with an AlexaFluor568-conjugated goat anti-mouse antibody (diluted 1:2000; Invitrogen) for 1.5 h at 41 C. For detection of pro-MMP-12 antibody (R&D Systems) was diluted 1:10 and detected using combinations of Alexa568-conjugated anti-goat and Alexa488-conjugated anti-mouse antibodies as described above. Cell nuclei were identified by counterstaining with Hoechst 33342 (2.5 mg ml À 1 ). Negative controls omitted primary antibodies. Staining was visualised by epifluorescence microscopy.
Differential tissue histology associated with MMP-7 expression in nodules
Sections from rheumatoid nodules with high (n ¼ 5) or low (n ¼ 6) MMP-7 expression were stained with a routine haematoxylin and eosin procedure, and then assessed in a 'blinded' manner by two investigators (NAH and Dr Tania Slatter, Department of Pathology, Dunedin, New Zealand). Each section was scored for collagen content, the extent of neutrophil influx and the presence of granuloma with necrosis formation ( Supplementary  Figures 1 and 2 .) For collagen content, the scoring was on a scale of 1 þ , where fibrinoid material predominated, through to 3 þ where collagen fibrils were intact, aligned and mature. Tissues that intermediate between these extremes were scored 2 þ . The extent of neutrophil influx was scored 1 þ when only occasional sparsely distributed neutrophils were present, 2 þ when neutrophils showed a patchy distribution and 3 þ when neutrophils were uniformly scattered throughout the tissue. Granuloma formation with accompanying necrosis was scored as 0 when absent or 1 when present.
Statistical analysis
The Mann-Whitney, two-sided U-test and Kruskal-Wallis test with post-test analysis by Dunn's multiple comparisons were used to analyse the results. Correlation coefficients were determined by rank correlation using nonparametric Spearman's test. Gender distribution and genotype frequencies were compared using a non-parametric, two-sided Fisher's exact test. Histological scores were averaged and then analysed using a nonparametric Kruskal-Wallis rank test.
All analyses were carried out using Prism 4 for Windows v.4.03 (GraphPad Software Inc., La Jolla, CA, USA) and STATA11 (StataCorp, College Station, TX, USA) statistical software. A probability level of 5% was considered significant for all statistical analyses.
Supplementary Information accompanies this paper on Genes and Immunity website (http://www.nature.com/gene)
